The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib

European Journal of Pharmacology

Volumn 570, Issue 1-3, 2007, Pages 175-181

  Nie, Qiang ^a   Wang, Zhen ^a   Zhang, Guo chun ^a   An, She juan ^a   Lin, Jia yin ^a   Guo, Ai lin ^a   Li, Rong ^a   Gan, Bin ^a   Huang, Ying ^a   Mok, Tony S ^b   Wu, Yi long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

EGF receptor intron1 (CA) n polymorphism; EGF receptor targeted inhibitors; Novel predictor; Targeted treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ADVANCED CANCER; ALLELE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MUTATIONAL ANALYSIS; NUCLEOTIDE REPEAT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN TOXICITY; SOMATIC MUTATION; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 34547841540     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.015     Document Type: Article

References (26)

1. Amador M.L., Oppenheimer D., Perea S., Maitra A., Cusati G., Iacobuzio-Donahue C., Baker S.D., Ashfaq R., Takimoto C., Forastiere A., and Hidalgo M. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64 (2004) 9139-9143
2. Buerger H., Packeisen J., Boecker A., Tidow N., Kersting C., Bielawski K., Isola J., Yatabe Y., Nakachi K., Boecker W., and Brandt B. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J. Pathol. 203 (2004) 545-550
3. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., Rossi E., Ludovini V., Gregorc V., Toschi L., Franklin W.A., Crino L., Gazdar A.F., Bunn Jr. P.A., and Hirsch F.R. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 23 (2005) 5007-5018
4. Chrysogelos S.A. Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res. 21 (1993) 5736-5741
5. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., Baird A., and Pazdur R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
6. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R.P., and Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21 (2003) 2237-2246
7. Gebhardt F., Zanker K.S., and Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274 (1999) 13176-13180
8. Henrion D., Amant C., Benessiano J., Philip I., Plantefeve G., Chatel D., Hwas U., Desmont J.M., Durand G., Amouyel P., and Levy B.I. Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro. J. Vasc. Res. 35 (1998) 356-362
9. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T., Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., and Tsai S.F. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10 (2004) 8195-8203
10. Janne P.A., Gurubhagavatula S., Yeap B.Y., Lucca J., Ostler P., Skarin A.T., Fidias P., Lynch T.J., and Johnson B.E. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 44 (2004) 221-230
11. Kang D., Gridley G., Huang W.Y., Engel L.S., Winn D.M., Brown L.M., Bravo-Otero E., Wu T., Diehl S.R., and Hayes R.B. Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet. Genomics 15 (2005) 343-347
12. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64 (2004) 8919-8923
13. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., and Kay A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
14. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
15. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., Camplese P.P., Iarussi T., Mucilli F., Mezzetti A., Cuccurullo F., Sacco R., and Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23 (2005) 857-865
16. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., Pizzo B., Tyson L., Venkatraman E., Ben-Porat L., Memoli N., Zakowski M., Rusch V., and Heelan R.T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 1103-1109
17. Moriai T., Kobrin M.S., Hope C., Speck L., and Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10217-10221
18. Moriai T., Kobrin M.S., and Korc M. Cloning of a variant epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 191 (1993) 1034-1039
19. Mu X.L., Li L.Y., Zhang X.T., Wang M.Z., Feng R.E., Cui Q.C., Zhou H.S., and Guo B.Q. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer. Res. 11 (2005) 4289-4294
20. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
21. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13306-13311
22. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., Mate J.L., Manegold C., Ono M., Queralt C., Jahan T., Sanchez J.J., Sanchez-Ronco M., Hsue V., Jablons D., Sanchez J.M., and Moran T. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11 (2005) 5878-5885
23. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., and Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
24. Tidow N., Boecker A., Schmidt H., Agelopoulos K., Boecker W., Buerger H., and Brandt B. Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res. 63 (2003) 1172-1178
25. Zhang W., Park D.J., Lu B., Yang D.Y., Gordon M., Groshen S., Yun J., Press O.A., Vallbohmer D., Rhodes K., and Lenz H.J. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin. Cancer Res. 11 (2005) 600-605
26. Zhang W., Stoehlmacher J., Park D.J., Yang D., Borchard E., Gil J., Tsao-Wei D.D., Yun J., Gordon M., Press O.A., Rhodes K., Groshen S., and Lenz H.J. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 5 (2005) 124-131